UK EXECUTIVE CHANGE SUMMARY: Ferguson Taps Former Ashtead, Bunzl Execs
UK EXECUTIVE CHANGE SUMMARY: Ferguson Taps Former Ashtead, Bunzl Execs
Read moreTo deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.
Find out MoreFri, 07th Aug 2020 08:17
UK EXECUTIVE CHANGE SUMMARY: Ferguson Taps Former Ashtead, Bunzl Execs
Read moreSyncona Portfolio Companies Boost Interim Result; Launches New Company
Read more(Sharecast News) - Healthcare company Syncona reported a "robust" performance for the six months up to 30 September in which its net assets reached a value of £1,366.7m at 203,4p per share and a net asset value total return of 9.6% in the period.
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreUK EXECUTIVE CHANGE SUMMARY: Kakuzi Acts To Prevent Human Rights Abuse
Read moreSyncona Investee Freeline Posts Widened Interim Loss On Higher Costs
Read more(Sharecast News) - Healthcare investment firm Syncona said on Friday that portfolio business Freeline Therapeutics had seen interim losses widen as a result of increased research and development costs.
Read moreUK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation
Read moreSyncona Life Science Portfolio Boosted By Autolus And Freeline
Read moreSyncona Investee Freeline Therapeutics Prices IPO In New York
Read moreUK TRADING UPDATE SUMMARY: Bluebird To Buy Southern Gold Venture Stake
Read moreSyncona Investee Freeline Therapeutics Files For Possible US Listing
Read more(Sharecast News) - Healthcare investor Syncona said its portfolio company Freeline Therapeutics has filed a registration statement with the US Securities and Exchange Commission for a proposed initial public offering (IPO).
Read moreSyncona's Investee Freeline Publishes Further Data For FLT180a
Read more